BNP Paribas Arbitrage SA Has $610,000 Stock Position in Bio-Rad Laboratories, Inc. (NYSE:BIO)

BNP Paribas Arbitrage SA trimmed its position in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 86.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,068 shares of the medical research company’s stock after selling 6,766 shares during the quarter. BNP Paribas Arbitrage SA’s holdings in Bio-Rad Laboratories were worth $610,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the stock. BlackRock Inc. boosted its holdings in shares of Bio-Rad Laboratories by 16.7% during the fourth quarter. BlackRock Inc. now owns 1,892,336 shares of the medical research company’s stock worth $1,103,119,000 after purchasing an additional 270,107 shares during the period. FMR LLC boosted its holdings in shares of Bio-Rad Laboratories by 20.5% during the fourth quarter. FMR LLC now owns 1,692,254 shares of the medical research company’s stock worth $986,483,000 after purchasing an additional 287,827 shares during the period. UBS Asset Management Americas Inc. boosted its holdings in shares of Bio-Rad Laboratories by 30.4% during the fourth quarter. UBS Asset Management Americas Inc. now owns 503,557 shares of the medical research company’s stock worth $293,544,000 after purchasing an additional 117,413 shares during the period. Brown Advisory Inc. boosted its holdings in shares of Bio-Rad Laboratories by 2.2% during the fourth quarter. Brown Advisory Inc. now owns 475,672 shares of the medical research company’s stock worth $277,289,000 after purchasing an additional 10,263 shares during the period. Finally, Alliancebernstein L.P. boosted its holdings in shares of Bio-Rad Laboratories by 20.4% during the first quarter. Alliancebernstein L.P. now owns 466,361 shares of the medical research company’s stock worth $266,371,000 after purchasing an additional 79,174 shares during the period. Institutional investors and hedge funds own 65.18% of the company’s stock.

Separately, Citigroup raised their price target on shares of Bio-Rad Laboratories from $675.00 to $750.00 and gave the stock a “buy” rating in a report on Friday, February 12th.

Shares of BIO opened at $602.97 on Friday. The company has a market capitalization of $17.95 billion, a price-to-earnings ratio of 4.43 and a beta of 0.83. The company’s 50 day simple moving average is $604.41. Bio-Rad Laboratories, Inc. has a twelve month low of $425.43 and a twelve month high of $689.00.

Bio-Rad Laboratories (NYSE:BIO) last issued its quarterly earnings data on Thursday, April 29th. The medical research company reported $5.21 earnings per share for the quarter, beating the consensus estimate of $2.50 by $2.71. The firm had revenue of $726.80 million for the quarter, compared to analyst estimates of $661.00 million. Bio-Rad Laboratories had a net margin of 151.73% and a return on equity of 4.55%. Analysts anticipate that Bio-Rad Laboratories, Inc. will post 12.07 earnings per share for the current fiscal year.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc develops, manufactures, and markets life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components.

Featured Article: Margin

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.